NCT00947388 - Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

September 30, 2012

Study Completion Date

March 31, 2013

Conditions

Recurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Chronic Lymphocytic LeukemiaStage IV Small Lymphocytic Lymphoma

Interventions

DRUG

Bendamustine Hydrochloride

Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy

BIOLOGICAL

Alemtuzumab

Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.

Trial Locations (2)

44106

Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

44195

Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland